MakeInfographics.ai

Gene Therapy & CRISPR Clinical Trials Progress 2026 Infographic

Data visualization tracking gene therapy and CRISPR-Cas9 clinical trial progress including FDA-approved therapies, active trials by disease area, investment trends, and breakthrough results.

Timelinegene therapy infographicCRISPR clinical trials statisticsgene editing data visualizationgene therapy facts and figuresCRISPR breakthroughs 2026
Gene Therapy & CRISPR Clinical Trials Progress 2026 infographic — Data visualization tracking gene therapy and CRISPR-Cas9 clinical trial progress including FDA-approved therapies, activ
Gene Therapy & CRISPR Clinical Trials Progress 2026 — Key data and statistics visualized. Source: MakeInfographics.ai
Share:

Generate a custom version of this infographic

Customize with your own data, style, and branding

Generate This Infographic

Key Milestones

1
15 gene therapies now FDA-approved, with 2,000+ active clinical trials globally (ClinicalTrials.gov, 2026)
2
Gene therapy clinical trials increased 340% from 455 in 2018 to 2,000+ in 2026 (Nature Medicine, 2026)
3
97% of CRISPR-treated sickle cell patients remain crisis-free at 24-month follow-up (Vertex, 2026)
4
CAR-T cell therapies generated $4.8B in 2025 sales across 6 approved products (EvaluatePharma, 2026)
5
Global gene therapy market reached $12.8B in 2026, projected $38B by 2030 (Grand View Research, 2026)
6
Gene therapy costs range from $373,000 to $3.5M per treatment (ICER, 2026)
7
CAR-T therapies show 42-54% five-year survival in previously untreatable cancers (NEJM, 2026)

Timeline of Gene Therapy & CRISPR Clinical Trials Progress 2026

Gene therapy and CRISPR gene editing have transitioned from laboratory breakthroughs to clinical reality, with an accelerating pipeline of approved therapies and active clinical trials. As of 2026, 15 gene therapies have received FDA approval, with over 2,000 active clinical trials globally — representing a 340% increase from 2018's trial count of 455.

The CRISPR revolution reached a landmark in December 2023 when the FDA approved Casgevy (exagamglogene autotemcel), the first CRISPR-based therapy, for sickle cell disease and transfusion-dependent beta-thalassemia. By 2026, three additional CRISPR therapies have reached market: one for hereditary angioedema, one for transthyretin amyloidosis, and an in vivo CRISPR treatment for a rare liver condition. Vertex Pharmaceuticals reports that 97% of Casgevy-treated sickle cell patients remain free of vaso-occlusive crises at 24-month follow-up.

Clinical trial landscape spans diverse disease areas. Oncology leads with 38% of all gene therapy trials, followed by rare genetic diseases (24%), neurological disorders (14%), cardiovascular disease (10%), infectious diseases (8%), and ophthalmology (6%). CAR-T cell therapies — a form of gene therapy for cancer — have generated the most clinical success, with six FDA-approved products generating $4.8 billion in 2025 sales. Kymriah and Yescarta continue to demonstrate 5-year survival rates of 42-54% in previously untreatable blood cancers.

Investment reflects growing confidence. Global gene therapy market revenue reached $12.8 billion in 2026, projected to exceed $38 billion by 2030. Venture capital investment in gene editing companies totaled $6.3 billion in 2025. Major pharmaceutical companies have collectively committed over $50 billion to gene therapy acquisitions and partnerships since 2020, including Pfizer's $5.4B acquisition of Global Blood Therapeutics and AbbVie's partnerships with CRISPR Therapeutics.

Challenges persist around manufacturing scale, durability of therapeutic effects, delivery systems for in vivo editing, and cost — current gene therapies range from $373,000 (Zolgensma for SMA) to $3.5 million (Hemgenix for hemophilia B), raising fundamental questions about healthcare system sustainability and equitable access.

Frequently Asked Questions

What diseases can gene therapy currently treat?
As of 2026, FDA-approved gene therapies treat: sickle cell disease and beta-thalassemia (Casgevy, Lyfgenia), spinal muscular atrophy (Zolgensma), certain inherited retinal dystrophies (Luxturna), hemophilia B (Hemgenix), several B-cell lymphomas and leukemias (CAR-T therapies: Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti), hereditary angioedema, and transthyretin amyloidosis. Clinical trials are actively investigating gene therapies for Duchenne muscular dystrophy, cystic fibrosis, Huntington's disease, Parkinson's disease, heart failure, HIV, and various solid tumors. The pipeline has expanded dramatically, with over 2,000 active trials across dozens of disease areas.
How does CRISPR gene editing work?
CRISPR-Cas9 works like molecular scissors guided by a GPS system. A guide RNA sequence is designed to match the target DNA location that needs editing. The Cas9 enzyme follows this guide RNA to the exact location in the genome, creates a precise double-strand break, and the cell's natural repair machinery either disables the gene (deletion) or inserts a corrected sequence (insertion/replacement). For sickle cell disease, CRISPR reactivates fetal hemoglobin production by disabling the BCL11A gene that normally shuts it off after birth. The edited cells are returned to the patient, producing healthy hemoglobin that compensates for the defective sickle hemoglobin.
Why are gene therapies so expensive?
Gene therapy costs ($373K-$3.5M) reflect several factors: extremely complex manufacturing (growing patient-specific cells, viral vector production), small patient populations for rare diseases (limiting economies of scale), decades of R&D investment, extensive quality testing requirements, and the one-time curative nature (replacing lifelong treatment costs). Hemgenix at $3.5M for hemophilia B is actually cost-effective compared to annual factor replacement therapy ($500K-800K/year for life). Manufacturers are working on next-generation delivery systems and manufacturing improvements that could reduce costs 60-80% by 2030. Outcomes-based payment models — where payers pay over time only if the therapy works — are emerging as a financing solution.

Sources

  • 1. ClinicalTrials.gov, Gene Therapy Trial Registry, 2026
  • 2. Nature Medicine, Gene Therapy Landscape Review, 2026
  • 3. Vertex Pharmaceuticals, Casgevy Long-Term Follow-Up Data, 2026
  • 4. Grand View Research, Gene Therapy Market Report, 2026
  • 5. New England Journal of Medicine, CAR-T Five-Year Survival Data, 2026

Embed This Infographic

Copy the code below to share this infographic on your website

<a href="https://www.makeinfographics.ai/infographic/gene-therapy-crispr-clinical-trials-2026" target="_blank" rel="noopener">
  <img src="https://www.makeinfographics.ai/images/infographics/gene-therapy-crispr-2026.webp"
       alt="Gene Therapy & CRISPR Clinical Trials Progress 2026 — Data visualization tracking gene therapy and CRISPR-Cas9 clinical trial progress including FDA-appro"
       width="960" height="540" loading="lazy"
       style="max-width:100%;height:auto;" />
</a>
<p>Source: <a href="https://www.makeinfographics.ai">MakeInfographics.ai</a> — Free AI Infographic Generator</p>

Create Your Own Gene Therapy & CRISPR Clinical Trials Progress 2026 Infographic

Customize this topic with your own data, style, and branding

Create Custom Version — Free

Related Infographics

The Solar System: Planets at Scale

A visual guide to our solar system — compare planet sizes, distances, temperatures, and key facts from Mercury to Neptune. Includes fascinating data on moons, rings, and extreme conditions.

Deep Ocean Zones and Marine Life

Dive into the five layers of the ocean — from the sunlit surface to the crushing depths of the hadal zone at 11,000 meters. Discover the unique creatures, extreme conditions, and mysteries of each depth layer.

CRISPR Gene Editing Breakthroughs & Applications 2026

Timeline of CRISPR milestones from discovery to approved therapies, covering clinical trials, agricultural applications, ethical debates, and the gene editing market outlook.

Space Debris & Orbital Pollution Data 2026

Comparative analysis of space debris by orbit type, generation sources, growth projections, cleanup technologies, and collision risk assessments for the space sustainability crisis.